SLC16A7 and breast carcinoma: Consistently, treatment of MCT2-expressing breast cancer cells with either β-hydroxybutyrate or co-culture with MGDAs enhances tumorigenic properties and leads to increased acetylation of histones and transcriptional upregulation of tumour-promoting genes such as IL-1β and LCN2 in breast cancer cells expressing MCT2.